Who Owns 23andMe?
23andMe is owned by TTAM Research Institute, a California nonprofit public benefit corporation founded and led by 23andMe co-founder Anne Wojcicki. TTAM acquired substantially all of the company's assets for approximately 305 million dollars in a bankruptcy court sale completed on July 14, 2025. The brand continues to sell DNA test kits and research services and operates the Lemonaid Health telehealth unit as a nonprofit.
Parent Company
Acquired
2025
Status
Private
Headquarters
23andMe Timeline
Who Owns 23andMe?
- Parent Company: TTAM Research Institute
- Ownership Type: Subsidiary
- Acquisition Year: 2025
- Company Type: Privately Held
| Brand | Parent Company | Ownership Type |
|---|---|---|
| 23andMe | TTAM Research Institute | Subsidiary |
Where to Buy
Disclosure: We may earn commission from purchases
23andMe on AmazonAdvertisement
History of 23andMe
- Founded: 2006
- Founders: Anne Wojcicki, Linda Avey, Paul Cusenza
- Acquired by TTAM Research Institute: 2025
23andMe was founded in 2006 in Mountain View, California, by Anne Wojcicki, Linda Avey, and Paul Cusenza. Wojcicki, a former healthcare investor and sister of YouTube CEO Susan Wojcicki, supplied the vision of consumer access to personal genetic information. The name refers to the 23 pairs of human chromosomes.
The company launched its spit-tube DNA test in 2007, offering ancestry and trait reports at a time when direct-to-consumer genetics was new. Time magazine named the product Invention of the Year in 2008. Growth was rapid until November 2013, when the FDA ordered 23andMe to stop marketing health-related genetic reports, forcing the company to strip health claims while it pursued regulatory clearance. It regained FDA authorization for carrier status reports in 2015 and gradually rebuilt its health portfolio, becoming the first company with FDA-authorized direct-to-consumer genetic health risk and cancer predisposition tests.
23andMe went public in June 2021 through a merger with Richard Branson's VG Acquisition Corp, a deal that valued it around 3.5 billion dollars. The stock peaked soon after and declined steadily as kit sales cooled and the company accumulated losses. A hacking incident disclosed in October 2023 exposed profile information of about 6.9 million users through credential stuffing, damaging trust and inviting lawsuits and state regulatory scrutiny.
Wojcicki made repeated attempts to take the company private in 2024 and early 2025, offering progressively lower bids that an independent board committee rejected. Facing a cash crunch, 23andMe filed Chapter 11 on March 23, 2025. Wojcicki stepped down as CEO and was replaced by CFO Joe Selsavage, and the stock was delisted from Nasdaq on March 31.
Advertisement
The bankruptcy sale produced the contested auction resolved in TTAM's favor for 305 million dollars. The purchase closed July 14, 2025, and the company continues to operate under TTAM's nonprofit structure. The former holding company's liquidation plan became effective December 5, 2025, with claims administration running through 2026.
About TTAM Research Institute
What does TTAM Research Institute own?
TTAM owns substantially all of the former 23andMe operating business, including the Personal Genome Service consumer DNA testing line, the 23andMe research services business, and the Lemonaid Health telehealth unit. It acquired these assets from 23andMe Holding Co. in July 2025.
Is TTAM Research Institute publicly traded?
Advertisement
No. TTAM is a nonprofit public benefit corporation and has no stock. It cannot be publicly traded, and no equity interests exist for public investors.
Who founded TTAM Research Institute?
Anne Wojcicki, the co-founder and former chief executive of 23andMe, founded and leads TTAM Research Institute. The name derives from the initials of her full name.
Where is TTAM Research Institute headquartered?
Advertisement
The organization is based in California, operating out of the San Francisco Bay Area, where 23andMe was historically headquartered.
How many brands does TTAM own?
Its principal consumer brand is 23andMe, plus the Lemonaid Health telehealth service and the 23andMe research business. The portfolio is small and concentrated in consumer health.
Who owns TTAM Research Institute?
Advertisement
Nobody owns it in the conventional sense. As a nonprofit public benefit corporation it has no shareholders and is controlled by its board of directors and mission charter. Anne Wojcicki founded the organization and leads it.
What is TTAM's relationship to Regeneron?
Regeneron Pharmaceuticals won the first bankruptcy auction for 23andMe's assets at 256 million dollars but lost the reopened auction when the court allowed TTAM to bid. TTAM ultimately won with a 305 million dollar offer, so Regeneron holds no ownership interest.
- Founded: 2025
- Headquarters: San Francisco, California, USA
- Company Type: Privately Held
Where Is 23andMe Made / Based?
- Headquarters: South San Francisco, California, USA
23andMe Categories & Tags
23andMe Sustainability & Ethics
The brand's defining ethical issue is the stewardship of genetic data. Under TTAM, the sale terms require the operator to preserve existing privacy policies, keep research participation opt-in, maintain a Consumer Privacy Advisory Board, and restrict future transfers of genetic data to owners with equivalent protections.
Advertisement
Privacy advocates remain watchful because the company's dataset is its most valuable asset. The nonprofit structure is intended to reduce incentives to monetize data in ways customers would not expect, but the commitments are contractual and their enforcement will be tested over time.
Awards & Recognition
Time magazine named 23andMe's DNA test its Invention of the Year in 2008, an early signal of the product's impact. The company has also appeared on Fast Company's most innovative companies lists, and its FDA authorizations for direct-to-consumer genetic health risk and BRCA reports were industry firsts that competitors later matched.
23andMe Recalls & Controversies
The brand's two largest controversies are regulatory and security related. In November 2013 the FDA ordered the company to stop selling health-related genetic interpretations, halting health reports for roughly two years until new authorizations were granted in 2015 and beyond.
In October 2023 a credential-stuffing attack exposed profile and relative-matching information of about 6.9 million users. The breach produced multiple lawsuits and investigations and was a central liability in the bankruptcy proceedings. During the 2025 sale, several US states objected to transferring genetic data without renewed opt-in consent; the court approved the sale with privacy conditions attached, including the Consumer Privacy Advisory Board.
Advertisement
23andMe Ownership: Pros & Cons
Advantages
- +Nonprofit ownership reduces pressure to monetize sensitive genetic data
- +Court-ordered privacy commitments give customers a written guarantee
- +Founder leadership preserves continuity of mission and brand
- +No public shareholders means no quarterly earnings pressure
Considerations
- -The brand carries the damage of the 2023 breach into its new structure
- -Nonprofit status narrows options for raising growth capital
- -The consumer DNA market is smaller than at its peak, limiting upside
- -State regulators continue to scrutinize genetic data transfers
- -The platform's value still depends on customer trust that was tested by bankruptcy
Frequently Asked Questions About 23andMe
Advertisement
Sources & Further Reading
Competitors to 23andMe
No direct competitors found in the same category. This could be because 23andMeoperates in a unique market segment or we're still building our competitor database.
Advertisement
Independent Alternatives to 23andMe
Looking for brands with different ownership structures? These similar brands are not owned by TTAM Research Institute, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsAdcock Ingram
Owned by Adcock Ingram Holdings Limited
South African pharmaceutical brand behind Panado and Myprodol, now privately held by Bidvest and NATCO Pharma.
pharmaceuticalsotchealthcare
Privately Owned
Adcock Ingram operates independently without a large parent corporation.
Healthcare PharmaceuticalsCresco Labs
Owned by Cresco Labs Inc.
Chicago-based cannabis company operating Sunnyside dispensaries and leading wholesale brands like Cresco, High Supply, and FloraCal.
cannabisdispensarysunnyside
Publicly Traded
Cresco Labs operates independently without a large parent corporation.
Healthcare PharmaceuticalsNexon Pharma
Owned by Nexon Pharma Sp. z o.o.
Polish dietary supplement and medical device brand owned by Nexon Pharma Sp. z o.o. of Warsaw, sold through pharmacies.
supplementsmedical-devicespoland
Privately Owned
Nexon Pharma operates independently without a large parent corporation.
Healthcare PharmaceuticalsAmazon Pharmacy
Owned by Amazon.com Inc.
Amazon's online pharmacy service offering prescription medications and home delivery, operating as a division of Amazon.com Inc.
pharmacymedicationshealthcare
Publicly Traded
Amazon Pharmacy is owned by Amazon.com Inc., a public company, a different structure than 23andMe's parent.
Healthcare PharmaceuticalsAmerisourceBergen
Owned by Cencora Inc.
Legacy brand name of Cencora Inc., one of the largest pharmaceutical distributors in the United States, formed through a 2001 merger and rebranded to Cencora in August 2023.
pharmaceutical-distributiondrug-distributionhealthcare-supply-chain
Publicly Traded
AmerisourceBergen is owned by Cencora Inc., a public company, a different structure than 23andMe's parent.
Healthcare PharmaceuticalsBausch + Lomb
Owned by Bausch + Lomb Corporation
Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.
contact-lensesvision-carebausch-lomb
Publicly Traded
Bausch + Lomb operates independently without a large parent corporation.
Jobs at TTAM Research Institute
Advertisement
Latest News About 23andMe
Related Articles About 23andMe
View more articles
Health
Hospital and Clinic Brand Ownership
HCA Healthcare is the largest for-profit hospital system (190 hospitals, $75.6B revenue). Tenet has 50 hospitals ($21.3B). UHS has 346 behavioral facilities. Fresenius leads dialysis. Explore our database.
Who Brands StaffNov 14, 2026
Hca HealthcareTenet HealthUhs
Health
Eye Care Brand Ownership: Bausch & Lomb to Alcon
J&J Vision (Acuvue) leads contact lenses at 27-30%. Alcon (Novartis spin-off) holds 25-27%. CooperVision has 22-24%. Bausch + Lomb has 12-15%. EssilorLuxottica dominates lenses at 30.7%. Explore our database.
Who Brands StaffNov 13, 2026
Bausch LombAlconCoopervision
Health
Dental Brand Ownership Beyond Colgate and Crest
Colgate holds 41.3% global toothpaste share. P&G (Crest, Oral-B) has 14.1%. Haleon (Sensodyne) has 4.4%. Church & Dwight is the only independent at scale. The oral care market is $47.2B. Explore our database.
Who Brands StaffNov 12, 2026
ColgateCrestOral B
Advertisement
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization